buy cheap toms shoes online 999,toms sale in usa virginia

buy cheap toms shoes online greece,toms sale in valencia 2016 ,buy cheap toms shoes online malaysia,toms sale in valencia 2016 13 ,buy cheap toms shoes online qatar,toms sale in valencia 2016 14 ,buy cheap toms shoes online quantity,toms sale in valencia 2016 kadrosu ,buy cheap toms shoes online yepme,toms sale in valencia 2016 moto2 ,buy cheap toms shoes review,toms sale in valencia 2016 motogp ,buy cheap toms shoes review australia,toms sale in valencia 2016 review ,buy cheap toms shoes review canada,toms sale in valencia 2016 specification ,buy cheap toms shoes review hiking,toms sale in valencia 2016 specifications ,buy cheap toms shoes review india,toms sale in valencia 2016 squad ,buy cheap toms shoes review isaac,toms sale in valencia bukidnon ,buy cheap toms shoes review podiatrist,toms sale in valencia ca ,buy cheap toms shoes review quality,toms sale in valencia ca 91355 ,buy cheap toms shoes review ratings,toms sale in valencia ca apartments ,buy cheap toms shoes review running,toms sale in valencia ca in ,

Cost, 'low price is no good medicine.' Some drug manufacturers have been better to return the feeling. 'Only generic drugs there is no future.' A person in charge of research and development pharmaceutical companies five years ago, he moved to new drug development, now has two new drugs in the review queue list, he believed that the limited growth potential of generics. Tackling forced transition of pressure, a lot of inventive pharmaceutical companies through OEM or OEM own brand of high-quality manner to domestic generic drugs to enter the markets of developed countries in Europe and America. This is similar to the OEM electronics industry suggest finding a way out for these pharmaceutical companies remains to be seen. Reform of heavy resistance when the economic volume and people's needs to a certain stage of development, change inevitably produce. In 1962 the US Congress passed amendments to the drug, the drug was first proposed not only to 'safe' must also be 'effective.' Today, China is experiencing this painful process. The last century, China to carry out the implementation of standardized quality management system certification for pharmaceutical research, production, distribution and other sectors to strengthen drug quality and safety control from the drug production process. In that round improvement in drug approval achieved landmark l GB, pharmaceutical production enterprises GMP certification, more than 7,000 pharmaceutical companies from the original reduced to more than 4,000. These measures enable the development level of generic drugs, the quality and safety significantly. After basic security protection, regulatory effectiveness starting to get the attention of public opinion, this is the trend in recent years. In 2006, academician Zhong Nanshan during the 'two sessions' to the Drug Administration Department to launch an attack, questioning why a time of so many drug number. Thereafter, the drug agency to start again for the pharmaceutical industry consolidation, while phasing out some companies and medicines, but still confined to rectify quality control. Since 2007, Food Drug Administration to tighten the criteria for approval of generic drugs, the new quality of generic drugs can be improved, but a huge number of historical debts will remain a drag on the overall quality of generic drugs at a low level. Beginning in 2009, the efficacy of the drug problem imitation States gradually into focus. Na analysis by the spring, by means of media reports of individual cases, some drugs will increase the problems for the industry as a whole torture, propelled the determination regulators remediation. The poor efficacy of generics expelled